Company news

Clarity Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Investor Presentation

March 25, 2024

Clarity launches $121 million equity raise

March 25, 2024

Trading Halt

March 24, 2024

First participant treated in the last dose escalation cohort

March 21, 2024

Theranostic prostate cancer trial advances to multi-dose

March 15, 2024

Additional COBRA trial data results

March 5, 2024

S&P DJI Announces March 2024 Quarterly Rebalance

March 1, 2024

Initial COBRA results

February 14, 2024

First patient dosed in Phase III prostate cancer trial

December 21, 2023

Recruitment closes for a diagnostic Phase II trial in NETs

December 18, 2023

Phase III CLARIFY trial in prostate cancer commences

November 29, 2023

undetectable PSA level with Cu-67 SAR-bisPSMA

November 29, 2023

SECuRE theranostic prostate cancer trial progresses

November 29, 2023

Bell Potter Healthcare Conference Presentation

November 14, 2023

Recruitment target achieved for Phase II SAR-Bombesin trial

November 6, 2023

Presentation for Wilsons Drug and Device Conference

October 26, 2023

First patient treated with Cu-67 SAR-Bombesin

October 2, 2023

Company Presentation E&P Small Cap Healthcare Conference

September 12, 2023

BOP preliminary trial results presented at EANM 2023

September 12, 2023

First neuroblastoma participant treated in highest cohort

August 25, 2023

First PC participant treated at the highest dose level

August 24, 2023

Theranostic prostate cancer trial advances to cohort 3

August 9, 2023

Clarity Bolsters Antibody Pre-Targeting with IP from MSK

August 6, 2023

Final Cohort opens for CL04 Paediatric Neuroblastoma trial

July 25, 2023

Phase II SABRE prostate cancer trial reaches 50% recruitment

July 23, 2023

Positive Guidance from FDA on Phase 3 Prostate Cancer Trial

July 3, 2023

Clarity Establishes US Center of Excellence for Research

June 27, 2023

Northstar Achieves Key Production Milestones

June 26, 2023

COMBAT theranostic prostate cancer trial commences in the US

June 19, 2023

Clarity expands supply of Cu-64 for Phase III trials

June 13, 2023

Presentation at Jefferies Healthcare Conference

June 12, 2023

Recruitment complete for Phase II prostate cancer trial

June 6, 2023

Theranostic prostate cancer trial advances to cohort 2

May 24, 2023

Clarity Receives $6.7 million R&D Tax Incentive Refund

April 18, 2023

Clarity Corporate Presentation

March 13, 2023

50% recruitment milestone for NET diagnostic Phase II trial

February 15, 2023

PROPELLER Trial Results

February 13, 2023

Diagnostic prostate cancer trial reaches recruitment target

February 8, 2023

Positive topline results from SAR-bisPSMA diagnostic trial

December 13, 2022

Managing Directors Presentation to AGM

November 23, 2022

Chairmans Address to Shareholders

November 23, 2022

IND approval from the FDA for theranostic SAR-Bombesin trial

November 20, 2022

Clarity Presentation -Bell Potter Healthcare Conference 2022

November 9, 2022

50% recruitment reached for Phase II prostate cancer trial

November 1, 2022

Corporate Presentation - Wilsons Drug and Device Conference

October 28, 2022

50% recruitment milestone reached for prostate cancer trial

October 26, 2022

First patient treated in therapeutic prostate cancer trial

October 6, 2022

First participant imaged in Phase II SAR-Bombesin trial

October 5, 2022

First participants imaged in SAR-Bombesin trial

September 13, 2022

Recruitment opens for Phase II trial in Prostate Cancer

September 4, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 22 decks. Every deck is listed under its year.